Biogen Inc. (BIIB)
Summary
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
In 12 days, on October 28, Biogen Inc. will publish its results for the third quarter. As a reminder, in late July, the company raised its FY 2026 non-GAAP diluted EPS underlying guidance from $15.25-$16.25 to $15.85-$16.85. In Q2, Biogen's Alzheimer's collaboration revenue rose 16% YoY to $63.7 million.
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) is expected to report a slight third-quarter earnings per share beat at $2.14, against a consensus of $2.07, when it reports on October 28, says Jefferies. Revenue should be in line at $2.6 billion, with lower cost of goods sold and research and development expenses partly offset by higher selling, general and administrative costs.
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 1,661 | $312,399.51 | $390,916.35 | $78,516.84 | 25.13% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 1,395 | $195,319.15 | $326,820.6 | $131,501.45 | 67.33% |
 Curtis Ellergodt Rothschild Investment LLC | 2,739 | $542,261.43 | $637,721.37 | $95,459.94 | 17.6% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 16,759 | $3.62M | $3.9M | $281,045.97 | 7.76% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 66,365 | $12.44M | $15.8M | $3.36M | 26.99% |
Biogen Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Salim Syed Mizuho | 458.9 | $95,657.16 | $108,290.6 | $12,633.44 | 13.21% |
 Chris Schott JP Morgan | 1,088.32 | $245,643.79 | $257,005.8 | $11,362.01 | 4.63% |
 Rajesh Kumar HSBC | -422.24 | $90,963.54 | $99,036.81 | -$8,073.27 | -8.88% |
Biogen Inc. (BIIB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biogen Inc. ever had a stock split?
Biogen Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher A. Viehbacher CEO | NASDAQ (NGS) Exchange | 09062X103 CUSIP |
| US Country | 7,500 Employees | - Last Dividend | 18 Jan 2001 Last Split | 16 Sep 1991 IPO Date |
Overview
Biogen Inc. is a pioneering biopharmaceutical company focused on discovering, developing, manufacturing, and delivering innovative therapies for neurological and neurodegenerative diseases. With a broad international presence, Biogen extends its reach across the United States, Europe, Germany, Asia, and other global regions. Since its founding in 1978, Biogen has been at the forefront of addressing some of the most challenging medical conditions, including multiple sclerosis (MS), spinal muscular atrophy, Alzheimer's disease, and psoriasis, among others. The company operates in collaboration with several notable industry partners, such as Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; and others, to advance its mission of transforming scientific discoveries into medical breakthroughs. Headquartered in Cambridge, Massachusetts, Biogen's commitment to improving patient care continues to drive its innovative research and drug development strategies.
Products and Services
Biogen's diverse portfolio showcases its dedication to treating complex neurological and neurodegenerative conditions:
- TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA: These products are part of Biogen's multiple sclerosis (MS) treatment range, addressing various aspects of MS management to improve patient quality of life.
- SPINRAZA: A groundbreaking therapy for spinal muscular atrophy, offering hope to individuals affected by this genetic disorder.
- ADUHELM: Part of Biogen's Alzheimer's disease portfolio, this drug represents a significant advancement in treating a condition that affects millions of individuals worldwide.
- FUMADERM: Developed for the treatment of plaque psoriasis, demonstrating Biogen's commitment to addressing autoimmune skin conditions.
- Biosimilars (BENEPALI, IMRALDI, FLIXABI, BYOOVIZ): These etanercept, adalimumab, infliximab, and ranibizumab biosimilars offer cost-effective alternatives to some of the most widely used biologic therapies for autoimmune diseases and macular degeneration.
- RITUXAN (and RITUXAN HYCELA), GAZYVA, OCREVUS: Biogen's offerings in the oncology and MS spaces, including treatments for non-Hodgkin's lymphoma, CLL, rheumatoid arthritis, and primary progressive MS, highlight the company's strong presence in developing therapies for both cancer and autoimmune diseases.
- LUNSUMIO, glofitamab, and other anti-CD20 therapies: These therapies are designed for patients with relapsed or refractory follicular lymphoma and non-Hodgkin's lymphoma, showcasing Biogen’s ongoing dedication to innovative cancer treatment.
In addition, Biogen's pipeline includes a broad array of projects targeting MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease, neuropsychiatry, genetic neurodevelopmental disorders, and the development of biosimilars. These initiatives, under various stages of development, signify Biogen's enduring commitment to expanding its impact on unmet medical needs and improving the lives of patients around the globe.
Contact Information
